Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

Australian biopharmaceutical company CSL has designated China as one of its most important strategic markets worldwide, a milestone highlighted by a significant expansion of both its workforce and ...

CSL shares have been under pressure, trading near $180, due to softer profits, rising costs, and slow plasma business recovery. Despite recent challenges, CSL's plasma collections, vaccine business, ...

The College Swimming League (CSL), a revolutionary sports enterprise, today unveiled its plans to fundamentally reimagine college swimming. Founded by Robert Kent and Kyle Sockwell, with support from ...

A report from the Australian National Audit Office into the ­Seqirus deal – and a separate agreement with US pharmaceutical company Moderna for an mRNA vaccine factory – argues the government strayed ...

Our fair value estimate is 30% higher than CSL's analyst price target of US$248 In this article we are going to estimate the intrinsic value of CSL Limited (ASX:CSL) by projecting its future cash ...

There’s a belief that I share, along with fellow PH contributor Stephen Dobie, that 2003 represented the absolute pinnacle of fast cars. And not just because the Compact is on an '03 plate. For those ...

Health editor Michael Smith on CSL’s remarkable story, why investors have fallen out of love with the healthcare giant and what Trump has to do with it. CSL was run like a bureaucracy until 1990 when ...

After all, how could one of Australia’s most admired companies, a global healthcare giant possibly be heading for a major correction? Yet here we are. The stock has done exactly what the charts warned ...

Drydocks World, a DP World company, and Cochin Shipyard Limited (CSL) have signed an Agreement of Heads of Terms to evaluate and develop India’s first ship repair cluster at the International Ship ...

SYDNEY (Reuters) -Australian biotech CSL has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu immunisation rates, which knocked its ...